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Abstract
Background: To determine the prevalence and associated factors with chronic kidney disease (CKD) in a cohort of HIV-
positive individuals with undetectable viral load on HAART.
Methods: From March, 2009 to September 2009, 213 individuals between 18-70 years, period on HAART $12 months, viral
load , 50 copies/mm
3, and CD4 $ 200 cells/mm
3, were consecutively enrolled at the outpatient clinic of Hospital de
Clı ´nicas, Porto Alegre, Brazil. Exclusion criteria were obesity, malnourishment, amputee, paraplegic, previous history of renal
disease, pregnancy and hepatic insufficiency. Renal function was determined by estimated glomerular filtration rate (eGFR)
assessed by the modification of diet in renal disease. CKD was defined as an eGFR less or equal than 60 ml/min/1.73 m
2, for
a period of at least 3 months. Poisson regression was used to determine factors associated with CKD.
Results: CKD was diagnosed in 8.4% of the population, and after adjustment, the risk factors were hypertension (RR=3.88,
95%CI, 1.84 - 8.16), time on HAART (RR=1.15, 95%CI,1.03–1.27) and tenofovir exposure (RR=2.25, 95%CI, 1.04–4.95). Higher
weight (RR=,0.88 95%CI, 0.82–0.96) was associated to normal function.
Conclusions: CKD was a common finding in this cohort of patients and was related to hypertension, time on HAART and
tenofovir exposure. We suggest a more frequent monitoring of renal function, especially for those with risk factors to early
identify renal impairment.
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Introduction
The advances of antiretroviral therapy (HAART) had turned
HIV/AIDS into a chronic disease [1–5]. As a consequence of
living longer, individuals might present complications not only
related to the virus, but also related to the treatment itself and
ageing process [1–4]. These complications might be related to
heart, lung, hepatic or renal diseases, for instance, which could be
associated to a higher mortality [2,3].
In this scenario, kidney disease has been increasingly reported,
with a prevalence of chronic kidney disease (CKD), varying from
4.7% to 7.6% according to several studies [5–8]. Risks that have
already been associated include the ‘‘traditional’’ factors related to
ageing, diabetes mellitus (DM) and hypertension [5,6]. Besides
that, other features such as the virus itself and some of the
antiretrovirals (ARVs) currently used, such as indinavir (IDV) and
tenofovir (TDF) have already been linked with nephrotoxicity in
these individuals [5,7,8].
The first stage of renal impairment is silent and only
detectable through laboratory analysis [9]. Although the most
used biomarker for renal dysfunction diagnosis, the measure-
ment of serum creatinine has limitations, such as the relatively
low sensitivity, which underestimates the underlying renal status,
and therefore, its values could be in the ‘‘normal range’’, even
after the loss of 50–60% of the glomerular filtration rate
(GFR) [9,10]. Although not clearly validated to HIV-infected
individuals, equations adjusting for muscle mass, age, weight,
ethnicity and sex, provide a more sensitive estimation of the
true renal function, and have been used in general popula-
tion (eGFR)[11,12]. Currently, the most common formulas to
estimate the GFR are Modification of Diet in Renal Disease
formula (MDRD) [13,14], Cockcroft-Galt (CG) [14,15] and
Chronic Kidney Disease Epidemiology Collaboration (CKD-epi)
[16].
The objectives of our study were to describe the prevalence of
CKD and to determine the risk factors associated to the
development of renal disease in a cohort of HIV infected
individuals on HAART, undetectable viral load, and not severely
immunosupressed (CD4 count . 200 cells/mm3), which would
better resemble the general population, in Brazil.
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Population
Two hundred fifty five patients attended in the HIV/AIDS
outpatient clinic at Hospital de Clı ´nicas, Porto Alegre, Brazil, were
consecutively enrolled from March, 2009 through September,
2009. To be included, patients needed to be on HAART and
undetectable viral load (,50 copies/ml) for a period equal or
greater than 12 months, CD4 counts higher than 200 cells/mm3
and age between 18 and 70 years. Patients were excluded if were
obese or malnourishment [17,18] due to the MDRD equation;
amputee and paraplegic (with decreased muscle mass), previous
history of kidney disease; present history of hepatitis B or C
infection (confirmed by a positive polymerase chain reaction) or
hepatic insufficiency; and, pregnant women.
Methods
Data were collected at the moment of the appointment and
included demographic variables (ethnicity, height, weight, BMI,
sex and age); diagnosis of DM (according to ‘‘The American
Diabetes Association’’)[19], use of antidiabetic agents; hyperten-
sion (according to the Joint National Comittee 7 [20]); a complete
history of HAART; use of drugs for prophylaxis against
opportunistic infections; CD4 cell counts (cells/mm
3, measured
by flow cytometry); plasma HIV-RNA level (copies/ml, measured
by b-DNA; HIV-1 RNA 3.0 assay, with limit of detection of 50
copies/ml); serum creatinine (mg/dl, measured by Jaffe ´; calibrated
method by isotope dilution mass spectrometry - IDMS); date of
HIV diagnosis and other comorbidities.
The biochemical data was measured in the same laboratory.
The main outcome of interest in our study was to eGFR assessed
by two measurements, at least, three months apart utilizing the
MDRD in its simplified version (which considers serum creatinine
concentration, age, sex and ethnicity) and CKD-epi equations.
CKD was defined as an eGFR less or equal than 60 ml/min per
1.73 m
2 or the presence of proteinuria independent of eGFR in
both estimations.
Renal function was classified in five stages depending on the
level of eGFR, as proposed by the Kidney Disease Outcomes
Quality Initiative (KDOQI): normal, GFR equal or higher 90 ml/
min per 1.73 m
2; mild decrease, GFR between 60–89 ml/min per
1.73 m
2 or presence of proteinuria with normal eGFR; moderate
decrease, GFR between 30-59 ml/min per 1.73 m
2; severe
decrease, GFR between 15–29 ml/min per 1.73 m
2; and, renal
failure or dialysis, GFR less than 15 ml/min per 1.73 m
2 [12].
The study was approved by the Research and Ethic Committee
of Hospital de Clinicas and all patients signed the informed
consent.
Statistical analysis
Statistical analysis included descriptive (mean and standard
deviation), univariate and multivariate analysis. Absolute and
relative frequencies were utilized for continuous and categorical
variables respectively.
To evaluate the association between CKD and categorical
variables Chi-square test or Fisher exact were applied as required.
Independent T test or one way ANOVA were used to compare
means; in case of asymmetry Mann Whitney test or Kruskal-Wallis
test were used. Variables significantly associated with renal
impairment in univariate analysis (p,0.05) were included in the
multivariate model. Those significant in the multivariate model
(p,0.1) were included in the final model. Poisson Regression was
used to determine the factors associated with CKD in an
univariate analysis and in a multivariate model. Pearson coefficient
and Bland-Altman graph were used to evaluate the correlation
and the concordance between the two equations to eGFR (MDRD
and CKD-epi). A p value of less than 0.05 was considered
significant. Analysis was performed using the statistical package for
the social sciences (SPSS) version 17.0 (SPSS Inc., Chicago,
Illinois, USA).
Sample size
The sample size calculation was based on a prevalence of at
least 4% of CKD in that population with a confidence level of
95%. A sample size of at least 198 individuals was needed to be
representative of the 2,050 individuals on HAART in our site to
have a power of 80%
Results
From the initial 255 included patients, there were 42 losses
(16.5%): 28 due to incomplete laboratory data; 13 withdrew the
informed consent; and, one additional patient died after signing
the consent. The characteristics and clinical variables of the
remained 213 patients are shown in Table 1. One hundred and
ten patients were men (51.6%), 174 were euro-descendants
(81.7%) and mean age was 45.6 years old, BMI was
24.7564.05; mean time on HAART was 7.764.7 years, mean
CD4+ count was 5686269 cells/mm
3, and mean nadir CD4
count was 1696137 cells/mm
3. The prevalence of hypertension
and DM was 20.7% (n=44) and 14.1% (n=30), respectively.
There was no statistical difference between ethnicity characteris-
tics (data not shown).
There was a significant correlation between the CKD-epi and
MDRD equations (Pearson coefficient = 0.9; p,0.001; Bland-
Altman graph analysis p=0.296; 95% IC -4.14–3.34, Figure 1).
The mean eGFR was 98.04630.35 ml/min/1.73 m2 for MDRD
and 96.37624.46 ml/min/1.73 m2 for CKD-epi (Table 2 shows
the eGFR by MDRD equation of the cohort).
The factors significantly associated with CKD in the univariate
models (table 3) were: hypertension, DM, time after HIV
diagnosis, older age, body weight, time on HAART, TDF and
ritonavir (RTV) exposure (100 mg/day). After adjustment by the
multivariate analysis (table 3), hypertension (RR=3.88, 95% CI
Table 1. Main demographic characteristics (data are
presented as mean 6 standard deviation or percentage).
N=213 (%)
Age (years) 45.6611,5
Men 110 (51.6 %)
Ethnicity
Euro-descendants 174 (81.7%)
Creatinine (mg/dl) 0.8960.32
Urea (mg/dl) 35.44 613.34
eGFR
a (ml/mim) 98.04630.35
CD4 (cells/mm
3) 569.816269
Hypertension 44 (20.7%)
Diabetes Mellitus 30 (14.1%)
Time on HAART
b (years) 7.864.8
aEstimated glomerular filtration rate,
bAntiretroviral therapy
doi:10.1371/journal.pone.0026042.t001
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1.03–1.27, p= 0.011), and TDF exposure (RR=2.25, 95% CI
1.04–4.95, p=0.038) remained significantly associated to CKD.
Higher weight (RR=0.89, 95% CI 0.82–0.96, p=0.005) was
significantly associated to a normal kidney function.
Discussion
Our study examined the prevalence of CKD and its associated
factors among HIV infected individuals on HAART for at least
one year and undetectable viral load (which is a quite clinically
stable population). The prevalence of CKD was 8.4%, which is
quite close, albeit higher, to the ones reported by other studies that
vary from 4.7% to 7.6% [21–26]. Although somehow expected,
this finding was worrisome for us, as it is estimated that about 5%
of the general Brazilian population older than 60 years is expected
to have CKD, whereas our cohort had a greater prevalence with
CKD with a mean age almost 15 years younger (mean age was
45.6 years) [27,28]. Likewise, as we selected HIV ‘‘healthy’’
patients (undetectable viral load and CD4 . 200 cells/3) and
without previous renal disease we were anticipating a lower
prevalence of CKD.
The factors associated were: hypertension, time on HAART
and TDF use. As expected, hypertension was found to be a major
risk factor associated with CKD (RR= 3.88, 95% CI 1.84–8.16)),
which is in accordance to other studies [5,6–8,22,24]. The risk was
slightly higher than the other studies, which varied from 1.68% to
3.8% [5,6,8].
Another unique finding was that time on antiretroviral therapy
was significantly associated with CKD. In our study, there was a
15% increased prevalence of CKD per year of additional exposure
to ARVs (RR=1.15, 95% CI 1.03–1.27). This could be explained
by the fact that prolonged use of HAART could be associated with
greater long term renal toxicity, meaning the more exposition
leading to higher toxicity.
Adverse effects of the exposure to individuals ARVs were
demonstrated by other studies which described the cumula-
tive association of TDF, ATV, indinavir and RTV to the
development of CKD [6,8]. In our study, the only antiretro-
viral that was independently associated to CKD, was TDF
(RR=2.25, 95% CI 1.04–4.95). Our findings were somewhat
Figure 1. Bland-Altman graph comparing MDRD and CKD-epi in individuals with chronic kidney disease. There was a concordance in
eGFR between the MDRD and CKD-epi equations in individuals with chronic kidney disease (the mean difference was 0.4161.90 ml). eGFR =
estimated glomerular filtration rate; MDRD = modified diet in renal disease; CKD-epi = chronic kidney disease epidemiology.
doi:10.1371/journal.pone.0026042.g001
Table 2. Prevalence of alteration in the renal function
according to Kidney Disease Outcomes Quality Initiative –
KDOQI [12], assessed by the modification of diet in renal
disease.
Rena Function eGFR
a (ml/min/1.73m
2) Our findings
N=213 (%)
Normal . or equal 90 127 (59.6)
Mild Reduction 60–89 68 (31.9)
Moderate Reduction 30–59 15 (7)
Severe Reduction 15–29 3 (1.4)
Renal failure or dialysis ,15 0
aEstimated Glomerular filtration rate
doi:10.1371/journal.pone.0026042.t002
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from 1.5 to 2.18 higher chance of renal disease [5,6,8]. We did not
have enough patients on indinavir (only 2) to find any association.
Perhaps with a larger sample we could come across major findings
regarding ritonavir use and, consequently, atazanavir, as it is the
antiretroviral used along with 100 mg of ritonavir daily.
An important finding was related to the body weight
(RR=0.89, 95% CI 0.82–0.96, which was significantly associated
as a protection factor. To our knowledge, this is the first study that
found this association. Individuals with lower body weight were at
greater risk of having CKD. Despite it is known that weight may
play an important function in drug metabolism, once it can
influence the bioavailability and pharmacokinetics of ARVs [29],
there is still limited data about the effect of weight in HAART.
Perhaps this should be a window of opportunity to individualize
ARVs dosage and minimize toxicity.
The study has several limitations that should be considered
when interpreting the results. Although all studies estimate the
GFR in HIV individuals, this could be not accurate enough to
allow a firm conclusion of kidney function. MDRD equation,
generally more accurate and utilized [11,13], might not be fully
applicable to specific populations. Limited data suggests that
MDRD may underestimate GFR in individuals with normal renal
function [11,13,16] and therefore have led to an overestimation
of renal impairment. We suggest that there is a need of an
individualized equation to estimate the GFR in each population.
Likely, due to constraints of MDRD, we excluded malnourished
and obese patients, which could have better contributed to some of
our findings. Secondly, our sample size might have limited our
findings as it may have not been large enough to detect all CKD
risk factors in this population, such as age and DM. Thirdly, this is
a cross sectional study and therefore we can only draw association
of events and not establish temporal sequence. Lastly, although we
tried to minimize HIV infection and its co-morbidities, selecting
individuals with CD4 counts greater than 200 cells/mm
3 and at
least one year with undetectable viral load, it is not possible to
exclude any influence of HIV infection and related diseases or
other nephrotoxic medications in the prevalence of renal
impairment [5].
In summary, according to our findings, in HIV population
which would most resemble the general population, hypertension,
time on HAART, and exposure to tenofovir were associated with a
higher prevalence of CKD. On the other hand, individuals with
higher body weight appeared to be ‘‘protected’’ from chronic
kidney disease. We suggest that an equation to eGFR should be
routinely applied to better identify decrease in renal function, and
should be performed at the moment of HIV diagnosis and later at
regular intervals, depending on the associated risk factors. Further
studies are necessary to confirm risks associated to renal disease in
HIV-infected individuals.
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